Chordate Medical trains neurologists in Liverpool – initiating the introduction of Ozilia® Migraine

During a neurology symposium with around 60 participants at The Walton Centre NHS Foundation Trust in Liverpool on October 6-7, Chordate Medical conducted a separate training on the company's treatment method, Ozilia® Migraine (formerly K.O.S). The Walton Centre is a leading neurology hospital in the UK, serving an area of about four million people, and the medical team's intention is to begin implementing Ozilia® into their treatment arsenal, starting with their private clinic side.

“Together with our clinical application specialist, Petra Libert, I had the opportunity to train seven specialist doctors and nurses on the practical use of the Ozilia® migraine treatment. It is very rewarding to work directly with the specialists who actually performs the treatment and helps patients, while also taking the first practical steps towards increasing business," says Anders Weilandt, Chordate Medical CEO.

The Walton Centre is a specialist hospital providing comprehensive neurological, neurosurgical, pain management, and rehabilitation services. The hospital has about 1,450 employees and treats over 140,000 patients each year.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact